# Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence

> **NCT03489265** · PHASE2 · WITHDRAWN · sponsor: **University of North Carolina, Chapel Hill**

## Conditions studied

- Fecal Incontinence
- Accidental Bowel Leakage
- Anal Incontinence
- Diarrhea
- Urge Incontinence

## Interventions

- **DRUG:** Eluxadoline 100 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03489265
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04
- **Primary completion:** 2019-09
- **Final completion:** 2020-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficult to recruit severely affected patients with fecal incontinence
- **Last updated:** 2019-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489265, "Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03489265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*